ResoTher Pharma is pleased to announce the signing of its first round of investment, lead by CAPNOVA A/S and consisting of a handful of private DK and US-based investors. CEO Lone Veng, PhD will take leadership of the new entity, whose goal it is to clinically validate a new peptide drug for resolution of inflammation. The drug, presently in preclinical development, is based on the world class science of Professor Mauro Perretti, Professor of Immunopharmacology and Dean of Research at Barts and the London School of Medicine. Co-founders and serial biotech entrepreneurs Thomas Jonassen, MD and Jeppe Øvlesen, MBA will take on roles as Chief Science Officer and Chief Financial Officer, respectively.
ResoTher Pharma closes seed round
|Published on: Nov 17, 2017||